US 8,802,137 B2 · Sustained release of antiinfectives

Abstract

Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

Claims59

Dependent claims

A liposomal aminoglycoside formulation comprising a liposome having a lipid bilayer and an aminoglycoside encapsulated therein, wherein the lipid bilayer comprises a neutral phospholipid and a sterol, the weight ratio of lipid to aminoglycoside in the formulation is 2:1 or less, and the liposome has a mean diameter of 0.1 microns to 0.5 microns.

Dependencies are inferred from the claim text.

Facts

Application

12/748,756Filed 29 Mar 2010 · continuation

Priority

29 Oct 2002

Published

US 2010/0260829 A114 Oct 2010

Granted

12 Aug 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 47/28
Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite: steroids, e.g. cholesterol, bile…
A61K 9/0078
Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy: for inhalation via a nebulizer…
A61K 9/127
Dispersions; Emulsions: synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/1277
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant: preparation processes;…

Family

Application60/421,923Us provisional application · filed 29 Oct 2002

Application10/696,389Parent of this continuation-in-part · filed 29 Oct 2003

Application11/023,971Parent of this continuation-in-part · filed 28 Dec 2004

Application11/185,448Parent of this continuation · filed 19 Jul 2005

US 2010/0260829 A1Pre-grant publication · published 14 Oct 2010

US 7,718,189 B2Parent of this continuation

Application11/185,448Parent of this continuation-in-part

US 7,544,369 B2Parent of this continuation-in-part

US 2004/0142026 A1Published application

US 2006/0073198 A1Published application

US 8,802,137 B2This patent

From the US filing history. Foreign family members aren’t listed.

Sustained release of antiinfectives

Life of this patent

Sustained release of antiinfectives

Life of this patent

Abstract

Claims59